Currently, clinically approved drugs targeting chemokines include anti-CCR4 antibodies (Mogamulizumab) and CXCR4 antagonists (Plerixafor, AMD3100), which are utilized in the treatment of hematological malignancies. Here, CXCR4 is linked to hematologic disorder.